Symbiox®  —— an innovative product in topic treatment of Psoriasis in worldwide for the past 30 years.

State CategoryⅠNew Drug、National Science and Technology Major Project、”Significant New Drugs Development”、obtained Intellectual Property Protection in China.

Delay relapse: After 12 weeks of treatment, patients in the benvitimod group achieved a median remission period of 36 weeks.

Better efficacy: 50 % of patients achieved PASI 75 at week 12 in the benvitimod group, which was significantly higher than that in either the calcipotriol group.

Higher safety: Almost no systemic adverse drug reactions were found.

Tripartite effects: Benvitimod can target to AhR, and prevent psoriasis recurrence.